pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,256 catalysts · 5,256 phase readout · 2,298 8k filing · 339 pdufa · 255 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 0 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: phase readout×clear all
type
  • phase readout5,256
  • 8k filing2,298
  • pdufa339
  • earnings255
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›TERMINATEDphase readoutNCT04709601: Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.

Sponsor: University of Texas Southwestern Medical Center. Phase: PHASE4. Conditions: Urinary Tract Infections

full page →ctgov ↗
›COMPLETEDphase readoutNCT06540612: Effects of Aerobic Exercise on Cancer-Related Biomarkers, Functional Capacity, Cognitive Status and Quality of Life in Women With Breast Cancer

Sponsor: Hasan Kalyoncu University. Phase: NA. Conditions: Breast Cancer Female, Quality of Life, Survivorship

full page →ctgov ↗
›COMPLETEDphase readoutNCT06545812: Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation

Sponsor: Josip Juraj Strossmayer University of Osijek. Phase: NA. Conditions: Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy, Inflammatory Response

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04645212: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Sponsor: Adverum Biotechnologies, Inc.. Phase: . Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07539181: Disclosing Agents as Photosensitizers in aPDT for Biofilm Control in Children

Sponsor: University of Nove de Julho. Phase: NA. Conditions: Dental Plaque

full page →ctgov ↗
›RECRUITINGphase readoutNCT07401719: Effects of Modified Clamshell Exercises in Patients With Hip Osteoarthritis Grade II.

Sponsor: Lahore University of Biological and Applied Sciences. Phase: NA. Conditions: Osteo Arthritis of Hip

full page →ctgov ↗
›RECRUITINGphase readoutNCT06104228: 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Sponsor: Bastiaan Driehuys. Phase: PHASE2. Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07434128: Mammogram Pretreatment With Ulipristal Acetate

Sponsor: OHSU Knight Cancer Institute. Phase: PHASE2. Conditions: Mammography Screening, Breast Density

full page →ctgov ↗
›COMPLETEDphase readoutNCT06797765: Optical Coherence Tomography Angiography in Neurological Disease

Sponsor: University of Texas Southwestern Medical Center. Phase: . Conditions: Octa, Stroke, Subarachnoid Hemorrhage, Intracerebral Hemorrhage

full page →ctgov ↗
›RECRUITINGphase readoutNCT04375800: Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE2. Conditions: Human Immunodeficiency Virus (HIV) Infection

full page →ctgov ↗
›RECRUITINGphase readoutNCT06271200: Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Sponsor: National Health Research Institutes, Taiwan. Phase: NA. Conditions: Metabolic Syndrome

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05283200: Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy

Sponsor: Imad Najm MD. Phase: NA. Conditions: Lifestyle

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03358303: Effects of Telemonitoring on the Outcome of Heart Failure Patients After an Incidence of Acute Decompensation

Sponsor: University Health Network, Toronto. Phase: NA. Conditions: Heart Failure

full page →ctgov ↗
›COMPLETEDphase readoutNCT04844827: Pleural Carcinomatosis Tissue Banking

Sponsor: Hospices Civils de Lyon. Phase: . Conditions: Pleural Effusion, Malignant

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05245942: Monitoring of the Safety and the Performance of the Endoscopic Cap Electrode (ECE50)

Sponsor: MED-EL Elektromedizinische Geräte GesmbH. Phase: . Conditions: Vocal Fold Paresis, Laryngeal Dystonia

full page →ctgov ↗
›COMPLETEDphase readoutNCT07398586: The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis

Sponsor: Second Affiliated Hospital of Wenzhou Medical University. Phase: PHASE4. Conditions: Ulcerative Colitis (UC)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07483073: A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Sponsor: Eli Lilly and Company. Phase: PHASE2. Conditions: Colitis, Ulcerative, Crohn Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT07147569: TAMBE Japan Post-Marketing Surveillance

Sponsor: W.L.Gore & Associates. Phase: . Conditions: Thoracoabdominal Aortic Aneurysm, Pararenal Aortic Aneurysm

full page →ctgov ↗
›RECRUITINGphase readoutNCT07007169: Mediterranean Diet and Inequality in Early Breast Cancer

Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark. Phase: PHASE2. Conditions: Early Breast Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07352683: Open TAP-block in Pediatric Abdominal Surgery

Sponsor: Uppsala University. Phase: NA. Conditions: Pain Management After Surgery

full page →ctgov ↗
›SUSPENDEDphase readoutNCT03580083: RGX-111 Gene Therapy in Patients With MPS I

Sponsor: REGENXBIO Inc.. Phase: PHASE1. Conditions: Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome, Hurler-Scheie Syndrome

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04106466: DBS for TRD With the Medtronic Summit RC+S

Sponsor: Helen Mayberg, MD. Phase: NA. Conditions: Major Depressive Disorder, Treatment Resistant Depression

full page →ctgov ↗
›RECRUITINGphase readoutNCT05492422: Central Executive Training and Parent Training for ADHD

Sponsor: Florida State University. Phase: NA. Conditions: ADHD

full page →ctgov ↗
›TERMINATEDphase readoutNCT04370522: Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Sponsor: Spanish Breast Cancer Research Group. Phase: . Conditions: Metastatic Breast Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT03920722: Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis

Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: PHASE3. Conditions: Microscopic Polyangiitis (MPA)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07502729: Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding

Sponsor: Shanghai Zhongshan Hospital. Phase: . Conditions: Portal Hypertension, Gastroesophageal Varices Hemorrhage, Gastric Varices, Esophageal Varices

full page →ctgov ↗
›AVAILABLEphase readoutNCT03123029: Expanded Access to Venetoclax

Sponsor: AbbVie. Phase: . Conditions: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07411924: Mastication, Cognition, and Nutritional Status in Multiple Sclerosis

Sponsor: Ondokuz Mayıs University. Phase: . Conditions: Multiple Sclerosis

full page →ctgov ↗
›RECRUITINGphase readoutNCT06564623: Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase: PHASE1. Conditions: Biliary Tract Cancers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07524023: Emotional-distress-based Integrated Care Programme in Patients With Stable COPD

Sponsor: University of Zurich. Phase: NA. Conditions: COPD, COPD (Chronic Obstructive Pulmonary Disease)

full page →ctgov ↗
›COMPLETEDphase readoutNCT04702880: A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Sponsor: Bristol-Myers Squibb. Phase: PHASE2. Conditions: Extensive-stage Small Cell Lung Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT00001979: Immune System Related Kidney Disease

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Phase: . Conditions: Kidney Disease, Nephrotic Syndrome

full page →ctgov ↗
›RECRUITINGphase readoutNCT06681246: The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment

Sponsor: Weizmann Institute of Science. Phase: NA. Conditions: Obesity, Weight Loss

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT00582296: Multi-Organ Screening Recommendations in Patients With Lynch Syndrome

Sponsor: Memorial Sloan Kettering Cancer Center. Phase: . Conditions: Lynch Syndrome

full page →ctgov ↗
›COMPLETEDphase readoutNCT05362903: A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Sponsor: Novartis Pharmaceuticals. Phase: . Conditions: Hypercholesterolemia

full page →ctgov ↗
›RECRUITINGphase readoutNCT07413042: A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

Sponsor: Peking University Cancer Hospital & Institute. Phase: PHASE1. Conditions: SCLC, Extensive Stage

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05932342: Improving Cognition of Older Adults in Community Housing

Sponsor: Centre for Addiction and Mental Health. Phase: NA. Conditions: Aging, Mental Disorder

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07218770: A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

Sponsor: Regeneron Pharmaceuticals. Phase: PHASE1. Conditions: Active Noninfectious Uveitis Affecting the Posterior Segment

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07469969: Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music Training Therapy for Chronic Subjective Tinnitus

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Phase: NA. Conditions: Chronic Subjective Tinnitus

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Sponsor: argenx. Phase: PHASE3. Conditions: Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome

full page →ctgov ↗
›RECRUITINGphase readoutNCT05302583: Aromatherapy Inhaler Use for HSCT Distress

Sponsor: Stanford University. Phase: NA. Conditions: Cancer Distress, Cancer Coping, Hematopoetic Stem Cell Transplant, Aromatherapy

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03648905: Clinical Laboratory Evaluation of Chronic Autonomic Failure

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS). Phase: . Conditions: Parkinson's Disease, Multiple System Atrophy, Autonomic Failure

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06642805: Bilio-pancreatic Complications of Congenital Duodenal Obstructions

Sponsor: University Hospital, Angers. Phase: . Conditions: Duodenal Obstruction

full page →ctgov ↗
›RECRUITINGphase readoutNCT06752356: A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor: Kedrion S.p.A.. Phase: PHASE3. Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

full page →ctgov ↗
›COMPLETEDphase readoutNCT06265051: Tirofiban After Successful MT Recanalization in AIS

Sponsor: Xiang Luo. Phase: PHASE2. Conditions: Acute Ischemic Stroke, Vessel Occlusion

full page →ctgov ↗
›RECRUITINGphase readoutNCT06553131: Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison

Sponsor: Loma Linda University. Phase: . Conditions: Neuromuscular Blockade

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07539129: Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation

Sponsor: Foundation University Islamabad. Phase: NA. Conditions: Acne Vulgaris

full page →ctgov ↗
›TERMINATEDphase readoutNCT04644029: Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE3. Conditions: HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis

full page →ctgov ↗
›COMPLETEDphase readoutNCT07320053: Effect of Longitudinal Care in Primary Health Care: An Analysis From the Patient's Perspective

Sponsor: IBS Granada. Phase: . Conditions: Age 65 and Older, Polypharmacy, Cronic Lung Disease, Mental Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Sponsor: Prescient Therapeutics, Ltd.. Phase: PHASE2. Conditions: CTCL

full page →ctgov ↗
← prev
page 42 of 106
next →